Lopinavir protein binding in HIV-1-infected pregnant women. - Wikidata - wikimedia - TriplyDB

Lopinavir protein binding in HIV-1-infected pregnant women.

Lopinavir protein binding in HIV-1-infected pregnant women.

http://www.wikidata.org/entity/Q33869395

about

Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics.Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment.Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.Global HIV/AIDS Clinical and Translational Pharmacology No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects.Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.Etravirine in CSF is highly protein bound Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines.Interpreting tacrolimus concentrations during pregnancy and postpartum.Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.Pharmacokinetic optimization of antiretroviral therapy in pregnancy.British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review).Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy.Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy.British HIV Association guidelines for the management of HIV infection in pregnant women 2012

P2860

Q28109657-1437FE7C-9EF9-4D58-AF2A-77F08D199DF9 Q34758192-2AD39057-6F3F-4C77-86B1-821E3025E5C9 Q35060812-408A42DA-A525-407F-A6C7-66F060C75E32 Q35689226-A8D85551-FB11-4AA5-B38E-D4A5C376EFD7 Q35960706-43020115-21BE-4894-83BF-495E77DF2CC4 Q36084313-411608F4-721E-482C-BBFF-F15D56BD96B9 Q36125023-57A12284-263A-41A3-A89B-97BBF27CFAE0 Q36439051-1F9988E8-EC0B-4111-8059-5C232D83D465 Q36727919-EA30665D-F076-450D-BEDD-38A33C8B18BB Q36762988-21F87328-3775-4A97-BB9E-8AD911904549 Q36763160-6A795286-0EBE-4591-8326-01AF16498384 Q36799909-51685BEC-B6D0-4A84-9486-50F558D19961 Q37600844-50F8AAE2-8578-4BD6-B111-61BB5609E6CE Q38047214-F92E8DAB-9396-4C52-AB4A-FCB473BDFFEB Q38325427-3DF87DC2-B83D-422A-85CC-58C3DEC1FF83 Q38846048-A309E427-FA89-4ADF-B08E-6DCF11F905D2 Q42600852-0F8DD1C9-8B63-494E-A588-712866B030CF Q46345016-7FFE7924-E044-4374-A3B9-7C5FC4A08CBE Q51366677-81EDA20B-EAE4-4A84-B369-B2937F55A917 Q57076282-992EFA5F-F899-4686-B9FD-38AE2F62AEE1

P2860

Lopinavir protein binding in HIV-1-infected pregnant women.

http://www.wikidata.org/entity/Q33869395

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Lopinavir protein binding in HIV-1-infected pregnant women.

@ast

Lopinavir protein binding in HIV-1-infected pregnant women.

@en

type

label

Lopinavir protein binding in HIV-1-infected pregnant women.

@ast

Lopinavir protein binding in HIV-1-infected pregnant women.

@en

prefLabel

Lopinavir protein binding in HIV-1-infected pregnant women.

@ast

Lopinavir protein binding in HIV-1-infected pregnant women.

@en

P1433

Q33869395-EC2559B6-93F3-4650-9AAB-D9996E8EE500

P1476

Q33869395-8AE68BB2-A3F1-4D57-8AAC-91AC18ED6FA6

P2093

Q33869395-07097DB6-C215-4DB8-942A-A972BC438827

Q33869395-0B0582E9-99DE-44B5-BA84-F218DBF54BBA

Q33869395-14BA4AE7-7A41-44C0-B2F4-06DFD6C00B0C

Q33869395-36F6DC8C-8D1F-447B-93E6-357A457AB9DD

Q33869395-39993832-0E6A-462D-9F4F-C338E7E1C09B

Q33869395-5BCB838D-32DE-431F-9BEF-95380D44569F

Q33869395-6941F97B-3B83-46FE-9E25-9373E7D809FC

Q33869395-84003B28-07C9-41DB-8F53-BF376C718726

Q33869395-8ACF6884-5689-4347-AFF3-4AFD1551EF88

Q33869395-9A42BDE6-BBB9-4E21-9682-97019AC7B717

P2860

Q33869395-19E2971F-B38C-400B-8E8C-2399458719AC

Q33869395-2098FD22-5CA3-4C5C-918E-65C04C376DA0

Q33869395-3373A761-0472-4451-BC65-00194ED85EDC

Q33869395-5BEA20E4-DB32-4C1C-9DB2-E3FE61DE75C5

Q33869395-5C676CE5-BDCF-458C-86B6-52FA5A105ACF

Q33869395-8156122E-3247-4360-BCA1-FD340FAB7A97

Q33869395-A607C8EF-59B7-4F91-880F-5E3C6C19645B

Q33869395-ADEB2021-265C-4EBB-B22F-600A9A0C604A

Q33869395-CE338AC1-C3A9-43CD-86EB-D2DA43FB3D05

Q33869395-D0117FF7-CC2E-44D6-958B-78EA201346AF

P304

Q33869395-2C4D6BB3-3ED0-4C3D-8240-B2BE2383D82C

P31

Q33869395-F3ED235F-C1E3-4557-A7BF-C9F9A0B252F3

P356

Q33869395-703B621F-38D0-4287-A729-63615889D148

P433

Q33869395-C649683B-45F4-4395-8CDC-F81779E4CA0D

P478

Q33869395-56E37045-EB43-465C-A1BF-E4BAF18A2135

P577

Q33869395-D76163B3-5442-4689-A19C-E68555055FFB

P5875

Q33869395-7009F769-8A18-470E-A988-B83FA6AAB291

P698

Q33869395-70E184B9-3FE9-4BB8-A494-D119BADA60C4

P921

Q33869395-7371AB70-350E-4821-8448-2ED350A05600

P932

Q33869395-BB0CE6C3-122F-4B32-960B-69703C4EEA62

P356

J.1468-1293.2009.00767.X

P1433

P1476

Lopinavir protein binding in HIV-1-infected pregnant women.

@en

P2093

A Hermes

http://www.w3.org/2001/XMLSchema#string

A Stek

http://www.w3.org/2001/XMLSchema#string

B M Best

http://www.w3.org/2001/XMLSchema#string

C Hu

http://www.w3.org/2001/XMLSchema#string

D Holland

http://www.w3.org/2001/XMLSchema#string

E V Capparelli

http://www.w3.org/2001/XMLSchema#string

F T Aweeka

http://www.w3.org/2001/XMLSchema#string

International Maternal Pediatr ...... (IMPAACT) P1026s Protocol Team

http://www.w3.org/2001/XMLSchema#string

J Read

http://www.w3.org/2001/XMLSchema#string

M Mirochnick

http://www.w3.org/2001/XMLSchema#string

P2860

HIV pharmacology: barriers to the eradication of HIV from the CNS.

Binding of lopinavir to human alpha1-acid glycoprotein and serum albumin.

Lopinavir exposure with an increased dose during pregnancy.

Plasma protein binding of drugs in pregnancy and in neonates.

Plasma protein binding of drugs in pregnancy.

Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy.

Reduced lopinavir exposure during pregnancy.

The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine.

Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions.

Changes in plasma drug binding and alpha 1-acid glycoprotein in mother and newborn infant.

P304

232-238

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1468-1293.2009.00767.X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40680658

http://www.w3.org/2001/XMLSchema#string

P698

20002783

http://www.w3.org/2001/XMLSchema#string

P921

P932

2874627

http://www.w3.org/2001/XMLSchema#string